Key Drivers
- High gross margin
- Large cash burn
- Negative equity
AIAI Summary
UroGen's transition from binary clinical optionality to a hybrid commercial-clinical company—backed by JELMYTO and early ZUSDURI revenue, a permanent J‑code, and a refinancing that extended runway—means the investment now hinges on execution: rapid conversion of PEFs to community dosing and clear quarterly revenue/FCF improvement within 12–24 months to avoid dilutive financings given negative equity and high burn.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Large cash burn
- •Negative equity
URGN displays very high gross margins and adequate short-term liquidity but is consuming cash with large operating losses, negative equity, and liabilities exceeding assets, making it a high-risk, overvalued speculative situation.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Defended support
- •High volatility
URGN is in a clear downtrend after a roughly 16–19% fall from ~$21.07 to $17.62 over the last month, with immediate support at $18.4–$18.8 (recent bounces) and resistance at $20.7–$21.7 that must be cleared to shift momentum.
~16–19% drop from $21.07 to $17.62 over the last month, underscoring elevated short-term volatility
Sentiment & News
Key News Insights:
- •Permanent J-code
- •Refinancing liquidity
- •Guidance withheld
UroGen is moving from clinical success to commercialization as ZUSDURI gains a permanent J-code and initial sales while a refinancing improves liquidity, but management is withholding near-term revenue guidance pending uptake.
Strong early reimbursement and financing de-risk near-term commercialization, but actual ZUSDURI uptake will determine whether revenue can stabilize cash burn and ease funding risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings